Markets finish week down after bouncing on Bannon's exit >>> READ MORE

Mergers and Acquisitions — The 5 Biggest Deals of Q2

These companies led the mergers and acquisitions charge in Q2

      View All  

Top Mergers and Acquisitions: Novartis (NVS) and GlaxoSmithKline (GSK)

mergers and acquisitions, buyoutsThe aborted Pfizer bid for AZN means that the pharma industry’s largest consummated deal came only to $20 billion. That’s the total value of assets that Novartis (NVS) and GlaxoSmithKline (GSK) agreed to swap in what amounted to major restructurings for both firms.

Novartis bought GlaxoSmithKline’s cancer drug business, GSK took Novartis’s vaccine business, and the companies agreed to combine their respective over-the-counter and consumer drug businesses. Whew.

All the big pharmaceuticals players are desperately trying to “focus” their businesses (read: cuts costs until revenue comes back), and — on paper, at least — this deal makes sense.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC